Answers are grounded in this paper and cite their sources.
Although thrombotic microangiopathy (TMA) is occasionally observed in patients with systemic sclerosis (SSc), thrombotic thrombocytopenic purpura (TTP) is extremely rare. Herein, we report a rare case of limited cutaneous SSc (lcSSc) complicated by TTP. A 44-year-old woman with anti-centromere antibody (ACA)-positive lcSSc of two years' duration presented with purpura, severe thrombocytopenia, and microangiopathic haemolytic anaemia. Her blood pressure, serum creatinine levels, and neurological examination results were normal. Although TTP, SSc-associated TMA, and scleroderma renal crisis (SRC) were considered in the differential diagnosis, plasma exchange alone was initially started because glucocorticoids (GCs) are associated with an increased risk of renal crisis. Subsequent testing revealed ADAMTS13 activity below 1%, with an inhibitor level of 1.0 Bethesda units (BU)/mL, establishing a diagnosis of acquired TTP. Despite starting prednisolone 40 mg/day, her platelet count dropped to 8,000/μL and she developed dysarthria, right hemiparesis, fever, and facial palsy. Moreover, her inhibitor level rose to 1.9 BU/mL after eight exchanges. GC pulse therapy and rituximab were added while plasma exchange continued. The platelet count recovered, and she has remained relapse-free for four years. A literature review identified 16 reports on 17 patients with SSc and TTP. None met current diagnostic criteria or had a documented ACA. In conclusion, acquired TTP can occur in ACA-positive lcSSc. Empirical GC therapy while awaiting the ADAMTS13 result may be considered in selected patients in whom TTP is strongly suspected and the estimated risk of SRC is low.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: